CareMax, Inc. (CMAX)
NASDAQ: CMAX · IEX Real-Time Price · USD
2.170
-0.180 (-7.66%)
At close: Jul 2, 2024, 4:00 PM
2.160
-0.010 (-0.46%)
After-hours: Jul 2, 2024, 7:53 PM EDT
CareMax Stock Forecast
CMAX's stock price has decreased by -97.57% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CareMax stock have an average target of 33.2, with a low estimate of 6.40 and a high estimate of 60. The average target predicts an increase of 1,429.95% from the current stock price of 2.17.
Analyst Consensus: Hold
* Price targets were last updated on Apr 1, 2024.
Analyst Ratings
The average analyst rating for CareMax stock from 2 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
UBS | UBS | Hold Maintains $7 → $6.4 | Hold | Maintains | $7 → $6.4 | +194.93% | Apr 1, 2024 |
UBS | UBS | Strong Buy → Hold Downgrades $150 → $30 | Strong Buy → Hold | Downgrades | $150 → $30 | +1,282.49% | Nov 17, 2023 |
Piper Sandler | Piper Sandler | Buy → Hold Downgrades $60 | Buy → Hold | Downgrades | $60 | +2,664.98% | Nov 10, 2023 |
UBS | UBS | Strong Buy Maintains $300 → $180 | Strong Buy | Maintains | $300 → $180 | +8,194.93% | Jan 6, 2023 |
Truist Securities | Truist Securities | Hold Initiates $225 | Hold | Initiates | $225 | +10,268.66% | Sep 7, 2022 |
Financial Forecast
Revenue This Year
913.89M
from 751.10M
Increased by 21.67%
Revenue Next Year
924.93M
from 913.89M
Increased by 1.21%
EPS This Year
-38.22
from -183.31
EPS Next Year
-23.06
from -38.22
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 945.0M | 1.0B | 1.2B | 1.4B | 1.8B |
Avg | 913.9M | 924.9M | 1.2B | 1.4B | 1.7B |
Low | 874.1M | 833.0M | 1.1B | 1.3B | 1.6B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 25.8% | 10.7% | 28.0% | 25.7% | 25.1% |
Avg | 21.7% | 1.2% | 24.3% | 22.2% | 21.4% |
Low | 16.4% | -8.9% | 19.5% | 17.3% | 16.7% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -39.34 | -23.74 | -12.79 |
Avg | -38.22 | -23.06 | -12.42 |
Low | -36.72 | -22.16 | -11.94 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.